Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
247 3 |
Ultima descărcare din IBN: 2024-04-17 21:22 |
SM ISO690:2012 ULINICI, Mariana, SULJIC, Alen, POGGIANELLA, Monica, MILAN BONOTTO, Rafaela, RESMAN RUS, Katarina, PARASCHIV, Angela, BONETTI, Amedeo Marco, TODIRAŞ, Mihail, CORLĂTEANU, Alexandru, GROPPA, Stanislav, CEBAN, Emil, PETROVEC, Miroslav, MARCELLO, Alessandro. Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova. In: Vaccines, 2023, vol. 11, supl. nr. 3, pp. 1-18. ISSN 2076-393X. DOI: https://doi.org/10.3390/vaccines11030637 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Vaccines | |
Volumul 11, Supliment nr. 3 / 2023 / ISSN 2076-393X | |
|
|
DOI:https://doi.org/10.3390/vaccines11030637 | |
Pag. 1-18 | |
Descarcă PDF | |
Rezumat | |
The early availability of effective vaccines against SARS-CoV-2, the aetiologic cause of COVID-19, has been at the cornerstone of the global recovery from the pandemic. This study aimed to assess the antispike RBD IgG antibody titres and neutralisation potential of COVID-19 convalescent plasma and the sera of Moldovan adults vaccinated with the Sinopharm BBIBP-CorV vaccine. An IgG ELISA with recombinant SARS-CoV-2 spike RBD and two pseudovirus-based neutralisation assays have been developed to evaluate neutralising antibodies against SARS-CoV-2 in biosafety level 2 containment facilities. A significant moderate correlation was observed between IgG titres and the overall neutralising levels for each neutralisation assay (ρ = 0.64, p < 0.001; ρ = 0.52, p < 0.001). A separate analysis of convalescent and vaccinated individuals showed a higher correlation of neutralising and IgG titres in convalescent individuals (ρ = 0.68, p < 0.001, ρ = 0.45, p < 0.001) compared with vaccinated individuals (ρ = 0.58, p < 0.001; ρ = 0.53, p < 0.001). It can be concluded that individuals who recovered from infection developed higher levels of antispike RBD IgG antibodies. In comparison, the Sinopharm-vaccinated individuals produced higher levels of neutralising antibodies than convalescent plasma. |
|
Cuvinte-cheie BBIBP-CorV, convalescent plasma, neutralisation assay, pseudovirus, RBD ELISA, SARS-CoV-2, Sinopharm, vaccine |
|
|